Oppenheimer Initiates Coverage On Immunogen with Perform Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has initiated coverage on Immunogen (NASDAQ:IMGN) with a Perform rating and a price target of $16.
October 06, 2023 | 9:39 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has initiated coverage on Immunogen with a Perform rating and a price target of $16.
The initiation of coverage by Oppenheimer, a major investment firm, is a significant event for Immunogen. The 'Perform' rating suggests that the firm expects the stock to perform in line with the market or its sector. The price target of $16 indicates where the firm believes the stock will trade in the future. This news could influence investor sentiment and potentially impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100